Hepatitis B virus immunopathology, model systems, and current therapies

Praneet Sandhu, Mohammad Haque, Tessa Humphries-Bickley, Swetha Ravi, Jianxun Song

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Most people develop acute hepatitis B virus (HBV)-related hepatitis that is controlled by both humoral and cellular immune responses following acute infection. However, a number of individuals in HBV-endemic areas fail to resolve the infection and consequently become chronic carriers. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Standard treatment in HBV infection includes IFN-α, nucleoside, or nucleotide analogs, which has direct antiviral activity and immune modulatory capacities. However, immunological control of the virus is often not durable. A robust T-cell response is associated with control of HBV infection and liver damage; however, HBV-specific T cells are deleted, dysfunctional, or become exhausted in chronic hepatitis patients. As a result, efforts to restore virus-specific T-cell immunity in chronic HBV patients using antiviral therapy, immunomodulatory cytokines, or therapeutic vaccination have had little success. Adoptive cell transfer of T cells with specificity for HBV antigen+ cells represents an approach aiming to ultimately eliminate residual hepatocytes carrying HBV covalently closed circular DNA (cccDNA). Here, we discuss recent findings describing HBV immunopathology, model systems, and current therapies.

Original languageEnglish (US)
Article number436
JournalFrontiers in immunology
Volume8
Issue numberAPR
DOIs
StatePublished - Apr 13 2017

Fingerprint

Hepatitis B virus
Antiviral Agents
Therapeutics
Virus Diseases
T-Lymphocytes
T-Cell Antigen Receptor Specificity
Hepatitis B Antigens
Viruses
Circular DNA
Immunomodulation
Adoptive Transfer
Chronic Hepatitis B
Chronic Hepatitis
Humoral Immunity
Infection
Nucleosides
Cellular Immunity
Hepatitis
Hepatocytes
Immunity

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Sandhu, P., Haque, M., Humphries-Bickley, T., Ravi, S., & Song, J. (2017). Hepatitis B virus immunopathology, model systems, and current therapies. Frontiers in immunology, 8(APR), [436]. https://doi.org/10.3389/fimmu.2017.00436
Sandhu, Praneet ; Haque, Mohammad ; Humphries-Bickley, Tessa ; Ravi, Swetha ; Song, Jianxun. / Hepatitis B virus immunopathology, model systems, and current therapies. In: Frontiers in immunology. 2017 ; Vol. 8, No. APR.
@article{2feac1fd06024c678d0d39cc3442c852,
title = "Hepatitis B virus immunopathology, model systems, and current therapies",
abstract = "Most people develop acute hepatitis B virus (HBV)-related hepatitis that is controlled by both humoral and cellular immune responses following acute infection. However, a number of individuals in HBV-endemic areas fail to resolve the infection and consequently become chronic carriers. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Standard treatment in HBV infection includes IFN-α, nucleoside, or nucleotide analogs, which has direct antiviral activity and immune modulatory capacities. However, immunological control of the virus is often not durable. A robust T-cell response is associated with control of HBV infection and liver damage; however, HBV-specific T cells are deleted, dysfunctional, or become exhausted in chronic hepatitis patients. As a result, efforts to restore virus-specific T-cell immunity in chronic HBV patients using antiviral therapy, immunomodulatory cytokines, or therapeutic vaccination have had little success. Adoptive cell transfer of T cells with specificity for HBV antigen+ cells represents an approach aiming to ultimately eliminate residual hepatocytes carrying HBV covalently closed circular DNA (cccDNA). Here, we discuss recent findings describing HBV immunopathology, model systems, and current therapies.",
author = "Praneet Sandhu and Mohammad Haque and Tessa Humphries-Bickley and Swetha Ravi and Jianxun Song",
year = "2017",
month = "4",
day = "13",
doi = "10.3389/fimmu.2017.00436",
language = "English (US)",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "APR",

}

Sandhu, P, Haque, M, Humphries-Bickley, T, Ravi, S & Song, J 2017, 'Hepatitis B virus immunopathology, model systems, and current therapies', Frontiers in immunology, vol. 8, no. APR, 436. https://doi.org/10.3389/fimmu.2017.00436

Hepatitis B virus immunopathology, model systems, and current therapies. / Sandhu, Praneet; Haque, Mohammad; Humphries-Bickley, Tessa; Ravi, Swetha; Song, Jianxun.

In: Frontiers in immunology, Vol. 8, No. APR, 436, 13.04.2017.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Hepatitis B virus immunopathology, model systems, and current therapies

AU - Sandhu, Praneet

AU - Haque, Mohammad

AU - Humphries-Bickley, Tessa

AU - Ravi, Swetha

AU - Song, Jianxun

PY - 2017/4/13

Y1 - 2017/4/13

N2 - Most people develop acute hepatitis B virus (HBV)-related hepatitis that is controlled by both humoral and cellular immune responses following acute infection. However, a number of individuals in HBV-endemic areas fail to resolve the infection and consequently become chronic carriers. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Standard treatment in HBV infection includes IFN-α, nucleoside, or nucleotide analogs, which has direct antiviral activity and immune modulatory capacities. However, immunological control of the virus is often not durable. A robust T-cell response is associated with control of HBV infection and liver damage; however, HBV-specific T cells are deleted, dysfunctional, or become exhausted in chronic hepatitis patients. As a result, efforts to restore virus-specific T-cell immunity in chronic HBV patients using antiviral therapy, immunomodulatory cytokines, or therapeutic vaccination have had little success. Adoptive cell transfer of T cells with specificity for HBV antigen+ cells represents an approach aiming to ultimately eliminate residual hepatocytes carrying HBV covalently closed circular DNA (cccDNA). Here, we discuss recent findings describing HBV immunopathology, model systems, and current therapies.

AB - Most people develop acute hepatitis B virus (HBV)-related hepatitis that is controlled by both humoral and cellular immune responses following acute infection. However, a number of individuals in HBV-endemic areas fail to resolve the infection and consequently become chronic carriers. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Standard treatment in HBV infection includes IFN-α, nucleoside, or nucleotide analogs, which has direct antiviral activity and immune modulatory capacities. However, immunological control of the virus is often not durable. A robust T-cell response is associated with control of HBV infection and liver damage; however, HBV-specific T cells are deleted, dysfunctional, or become exhausted in chronic hepatitis patients. As a result, efforts to restore virus-specific T-cell immunity in chronic HBV patients using antiviral therapy, immunomodulatory cytokines, or therapeutic vaccination have had little success. Adoptive cell transfer of T cells with specificity for HBV antigen+ cells represents an approach aiming to ultimately eliminate residual hepatocytes carrying HBV covalently closed circular DNA (cccDNA). Here, we discuss recent findings describing HBV immunopathology, model systems, and current therapies.

UR - http://www.scopus.com/inward/record.url?scp=85018438297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018438297&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.00436

DO - 10.3389/fimmu.2017.00436

M3 - Review article

C2 - 28450868

AN - SCOPUS:85018438297

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - APR

M1 - 436

ER -